Gyre reports Q2 2026 results, advances F351 NDA and Cullgen pipeline
China's CDE accepted the NDA for hydronidone in liver fibrosis and Gyre started a new lung injury trial, while the company affirmed its full-year revenue guidance.
SEC filing
Latest
3 stories
Friday, August 7
Thursday, July 16
Gyre Therapeutics adds three directors to board effective August 1, 2026
The Nasdaq-listed biopharma named CSO Yue Xiong, industry veteran Maxwell Kirkby, and biotech executive Claire Weston to its board.
SEC filing
Wednesday, July 15
Cullgen discloses 2025 results and merger deal with Gyre Therapeutics
Cullgen's audited 2025 financials, filed with Gyre's SEC report, detail its Astellas collaboration and a March 2026 merger agreement with Gyre.
SEC filing